Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 17/20 | 0.76 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.76 |
| ▸ | KDR | P35968 | 2/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.58 |
| ▸ | IGF1R | P08069 | 1/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.58 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.58 |
| ▸ | CDK2 | P24941 | 1/20 | 0.58 |
| ▸ | CSK | P41240 | 1/20 | 0.58 |
| ▸ | JAK3 | P52333 | 1/20 | 0.58 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.57 |
| ▸ | FLT4 | P35916 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5132903 | 0.93 | AURKA (0.66) | AURKAAURKBKDREGFRIGF1R | |
| SCHEMBL5132902 | 0.92 | AURKA (0.65) | AURKAAURKBKDREGFRIGF1R | |
| SCHEMBL3429981 | 0.92 | AURKA (0.65) | AURKAAURKBKDREGFRIGF1R | |
| SCHEMBL5043023 | 0.92 | AURKA (0.64) | AURKAAURKBKDREGFRIGF1R | |
| SCHEMBL3429987 | 0.92 | AURKA (0.64) | AURKAAURKBKDREGFRIGF1R | |
| SCHEMBL6027924 | 0.91 | AURKA (0.75) | AURKAAURKBKDREGFRIGF1R | |
| SCHEMBL5043688 | 0.89 | AURKA (0.76) | AURKAAURKBPDGFRB | |
| SCHEMBL3429837 | 0.89 | AURKA (0.81) | AURKAAURKBKDREGFRIGF1R | |
| SCHEMBL3431187 | 0.89 | AURKA (0.81) | AURKAAURKBKDREGFRIGF1R | |
| SCHEMBL5039292 | 0.89 | AURKA (0.74) | AURKAAURKBKDREGFRCSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1635837-B1 | (3-((QUINAZOLIN-4-YL)AMINO)-1H-PYRAZOL-1-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ASTRAZENECA AB (SE) | 2008-07-16 | — | — | EP | claimed |
| US-20060135541-A1 | (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | claimed |
| EP-1635837-B1 | (3-((QUINAZOLIN-4-YL)AMINO)-1H-PYRAZOL-1-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ASTRAZENECA AB (SE) | 2008-07-16 | — | — | EP | disclosed |
| US-20060135541-A1 | (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer | ASTRAZENECA AB (SE) | 2006-06-22 | — | — | US | disclosed |
| EP-1635837-A1 | (3-((QUINAZOLIN-4-YL)AMINO)-1H-PYRAZOL-1-YL)ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | AstraZeneca AB (SE) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004105764-A1 | (3- ((QUINAZOLIN-4-YL) AMINO )-1H-PYRAZOL-1-YL) ACETAMIDE DERIVATIVES AND RELATED COMPOUNDS AS AURORA KINASE INHIBITORS FOR THE TREATMENT OF PROLIFERATIVE DISEASES SUCH AS CANCER | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135541-A1 | (3-((Quinazolin-4-yl) amino)-1h-pyrazol-1-yl)acetamide derivatives and related compounds as aurora kinase inhibitors for the treatment of proliferative diseases such as cancer | CDK19, CDK16, AURKC | AURKA 4/4885AURKB 16/4885KDR 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.